



PATENT
ATTY. DOCKET NO.: STEM1110-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Twardzik, *et al.* Art Unit: 1647
Application No.: 10/039,119 Examiner: Unassigned
Filed: January 4, 2002
Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

TRANSMITTAL LETTER

Sir:

Transmitted herewith for the above-identified application please find:

1. Statement Under 37 C.F.R. §§ 1.821(f) and (g) (1 pg.);
2. Verified Statement Under 37 C.F.R. § 1.821(f) (1 pg.);
3. Response to Notice to Comply with Sequence Listing Requirements Under 37 C.F.R. §§ 1.821-1.825 (2 pgs.);
4. Sequence Listing (3 pgs.);
5. Sequence Listing in computer readable form (3.5" disk);
6. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pgs.); and
7. Return Postcard

RECEIVED
APR 15 2002
TECH CENTER 1600/290

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, April 5, 2002, in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Mikhail Bayley

Name of Person Mailing Paper

Mikhail Bayley

April 5, 2002

Signature

Date


In re Application of:
Twardzik *et al.*
Application No.: 10/039,119
Filed: January 4, 2002
Page 2

PATENT
ATTY. DOCKET NO.: STEM1110-4

No fee is deemed necessary in connection with the filing of this paper. However, if any fee is required, the Commissioner is hereby authorized to charge the amount of this fee, or credit any overpayments, to Deposit Account No. 50-1355. A copy of this Transmittal Sheet is enclosed.

Respectfully submitted,

Date: April 5, 2002


Lisa A. Haile, Ph.D.
Reg. No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

USPTO Customer Number: 28213

PATENT DOCKETING

FEB 12 2002

GRAYCARY/TELLIS
UNITED STATES PATENT AND TRADEMARK OFFICECOMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D. C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/039,119	01/04/2002	Daniel R. Twardzik	STEM1110-4

28213
GARY CARY WARE & FRIENDENRICH LLP
4365 EXECUTIVE DRIVE
SUITE 1600
SAN DIEGO, CA 92121-2189

TECH CENTER 1600/2900
APR 15 2002
RECEIVED

CONFIRMATION NO. 1736

FORMALITIES LETTER



OC000000007433247

Date Mailed: 02/06/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Manuela Bayle
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Twardzik, *et al.* Art Unit: 1647
Application No.: 10/039,119 Examiner: Unassigned
Filed: January 4, 2002
Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

Sir:

I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

Respectfully submitted,

Date: April 5, 2002

Lisa A. Haile
Lisa A. Haile, Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>April 5, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	<i>Mikhail Bayley</i>
Signature	Date April 5, 2002



PATENT
ATTY. DOCKET NO.: STEM1110-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Twardzik, *et al.* Art Unit: 1647
Application No.: 10/039,119 Examiner: Unassigned
Filed: January 4, 2002
Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Date: 04/04/2002

Mikhail Bayley
Mikhail Bayley

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>April 5, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	April 5, 2002
Signature	Date



PATENT
ATTY. DOCKET NO.: STEM1110-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Twardzik, *et al.* Art Unit: 1647
Application No.: 10/039,119 Examiner: Unassigned
Filed: January 4, 2002
Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

RESPONSE TO NOTICE TO COMPLY

WITH SEQUENCE LISTING REQUIREMENTS UNDER 37 C.F.R. §§ 1.821-1.825

Dear Sir:

In response to the notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures mailed February 6, 2002, Applicant provides herewith a computer readable and a paper copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821 *et seq.*

Please amend the application as follows:

In the Specification:

Following the abstract, please insert the attached Sequence Listing with subsequent page numbering thereafter.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>April 5, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	April 5, 2002
Signature	Date

In re Application of:
Twardzik *et al.*
Application No.: 10/039,119
Filed: January 4, 2002
Page 2

PATENT
ATTY. DOCKET NO.: STEM1110-4

If the Examiner would like to discuss any of the issues raised in this Amendment or the attached sequence listing, Applicants' representative can be reached at (858) 677-1456.

Respectfully submitted,

Date: April 5, 2002

By: Richard D. Haile *Reg. No. 38,347*

Lisa A. Haile, Ph.D.
Reg. No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

USPTO Customer Number: 28213